Experienced in Diffuse Midline Glioma H3 K27M-Mutant

Dr. Elaine R. Morgan

Pediatric Hematology Oncology
225 E Chicago Ave, 
Chicago, IL 
Experienced in Diffuse Midline Glioma H3 K27M-Mutant
225 E Chicago Ave, 
Chicago, IL 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Elaine Morgan is a Pediatric Hematologist Oncology provider in Chicago, Illinois. Dr. Morgan is rated as an Experienced provider by MediFind in the treatment of Diffuse Midline Glioma H3 K27M-Mutant. Her top areas of expertise are Acute Lymphoblastic Leukemia (ALL), Childhood Acute Myeloid Leukemia, Febrile Neutropenia, and Leukemia.

Her clinical research consists of co-authoring 20 peer reviewed articles and participating in 8 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Pediatric Hematology Oncology
Licenses
Pediatric Hematology-Oncology in IL
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Meridian Choice
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
View 3 Less Insurance Carriers -

Locations

225 E Chicago Ave, Chicago, IL 60611

Additional Areas of Focus

Dr. Morgan has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Immune Thrombocytopenic Purpura (ITP)

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

8 Clinical Trials

Risk-Stratified Randomized Phase III Testing of Blinatumomab (NSC#765986) in First Relapse of Childhood B-Lymphoblastic Leukemia (B-ALL)
Risk-Stratified Randomized Phase III Testing of Blinatumomab (NSC#765986) in First Relapse of Childhood B-Lymphoblastic Leukemia (B-ALL)
Enrollment Status: Active_not_recruiting
Publish Date: October 15, 2025
Intervention Type: Drug, Procedure, Biological, Other, Radiation
Study Drugs: Asparaginase, Blinatumomab, Cyclophosphamide, Cytarabine, Dexamethasone, Etoposide, Leucovorin Calcium, Mercaptopurine, Methotrexate, Mitoxantrone, Mitoxantrone Hydrochloride, Pegaspargase, Hydrocortisone, Thioguanine, Vincristine, Vincristine Sulfate
Study Phase: Phase 3
International Phase 3 Trial in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ALL) Testing Imatinib in Combination With Two Different Cytotoxic Chemotherapy Backbones
International Phase 3 Trial in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ALL) Testing Imatinib in Combination With Two Different Cytotoxic Chemotherapy Backbones
Enrollment Status: Active_not_recruiting
Publish Date: September 19, 2025
Intervention Type: Drug, Procedure, Other, Biological
Study Drugs: Cyclophosphamide, Cytarabine, Daunorubicin Hydrochloride, Dexamethasone, Dexrazoxane Hydrochloride, Doxorubicin, Etoposide, Filgrastim, Ifosfamide, Imatinib Mesylate, Leucovorin Calcium, Mercaptopurine, Methotrexate, Methylprednisolone, Pegaspargase, Prednisolone, Hydrocortisone, Thioguanine, Vincristine Sulfate
Study Phase: Phase 3
A Phase III Randomized Trial for Newly Diagnosed High Risk B-Lymphoblastic Leukemia (B-ALL) Including a Stratum Evaluating Dasatinib (NSC#732517) in Patients With Ph-like Tyrosine Kinase Inhibitor (TKI) Sensitive Mutations
A Phase III Randomized Trial for Newly Diagnosed High Risk B-Lymphoblastic Leukemia (B-ALL) Including a Stratum Evaluating Dasatinib (NSC#732517) in Patients With Ph-like Tyrosine Kinase Inhibitor (TKI) Sensitive Mutations
Enrollment Status: Active_not_recruiting
Publish Date: August 21, 2025
Intervention Type: Drug, Other, Radiation
Study Drugs: Clofarabine, Cyclophosphamide, Cytarabine, Dasatinib, Daunorubicin Hydrochloride, Dexamethasone, Doxorubicin Hydrochloride, Etoposide, Hydrocortisone Sodium Succinate, Leucovorin Calcium, Mercaptopurine, Methotrexate, Pegaspargase, Prednisone, Thioguanine, Vincristine Sulfate
Study Phase: Phase 3
Risk-Stratified Therapy for Acute Myeloid Leukemia in Down Syndrome
Risk-Stratified Therapy for Acute Myeloid Leukemia in Down Syndrome
Enrollment Status: Active_not_recruiting
Publish Date: August 01, 2025
Intervention Type: Drug, Other
Study Drugs: Asparaginase, Erwinia Asparaginase, Cytarabine, Daunorubicin, Etoposide, Mitoxantrone, Thioguanine
Study Phase: Phase 3
Treatment of Patients With Newly Diagnosed Standard Risk B-Lymphoblastic Leukemia (B-ALL) or Localized B-Lineage Lymphoblastic Lymphoma (B-LLy)
Treatment of Patients With Newly Diagnosed Standard Risk B-Lymphoblastic Leukemia (B-ALL) or Localized B-Lineage Lymphoblastic Lymphoma (B-LLy)
Enrollment Status: Active_not_recruiting
Publish Date: April 01, 2025
Intervention Type: Other, Drug
Study Drugs: Cyclophosphamide, Cytarabine, Dexamethasone, Doxorubicin Hydrochloride, Leucovorin Calcium, Mercaptopurine, Methotrexate, Pegaspargase, Thioguanine, Vincristine Sulfate
Study Phase: Phase 3
A Groupwide Pilot Study to Test the Tolerability and Biologic Activity of the Addition of Azacitidine (IND# 133688, NSC# 102816) to Chemotherapy in Infants With Acute Lymphoblastic Leukemia (ALL) and KMT2A(MLL) Gene Rearrangement
A Groupwide Pilot Study to Test the Tolerability and Biologic Activity of the Addition of Azacitidine (IND# 133688, NSC# 102816) to Chemotherapy in Infants With Acute Lymphoblastic Leukemia (ALL) and KMT2A(MLL) Gene Rearrangement
Enrollment Status: Completed
Publish Date: February 27, 2025
Intervention Type: Procedure, Drug
Study Drugs: Azacitidine, Cyclophosphamide, Cytarabine, Daunorubicin, Dexamethasone, Hydrocortisone, Leucovorin, Mercaptopurine, Methotrexate, PEG-Asparaginase, Prednisolone, Thioguanine, Vincristine
Study Phase: Phase 2
Classification of Newly Diagnosed Acute Lymphoblastic Leukemia (ALL)
Classification of Newly Diagnosed Acute Lymphoblastic Leukemia (ALL)
Enrollment Status: Completed
Publish Date: October 03, 2023
Intervention Type: Other
A Children's Oncology Group Protocol for Collecting and Banking Relapsed Acute Lymphoblastic Leukemia Research Specimens
A Children's Oncology Group Protocol for Collecting and Banking Relapsed Acute Lymphoblastic Leukemia Research Specimens
Enrollment Status: Completed
Publish Date: January 18, 2020
Intervention Type: Other
View 7 Less Clinical Trials

20 Total Publications

Real-world generalizability of clinical trial cytomolecular risk in pediatric acute myeloid leukemia: a report from the REAL-AML cohort.
Real-world generalizability of clinical trial cytomolecular risk in pediatric acute myeloid leukemia: a report from the REAL-AML cohort.
Journal: Journal of the National Cancer Institute
Published: May 20, 2025
Similar Doctors
Distinguished in Diffuse Midline Glioma H3 K27M-Mutant
Dr. Andres E. Morales
Pediatric Hematology Oncology
Distinguished in Diffuse Midline Glioma H3 K27M-Mutant
Dr. Andres E. Morales
Pediatric Hematology Oncology
5841 S Maryland Ave, Mc 4060, 
Chicago, IL 
 (7.5 miles away)
773-702-6808
Languages Spoken:
English

Andres Morales is a Pediatric Hematologist Oncology provider in Chicago, Illinois. Dr. Morales is rated as an Advanced provider by MediFind in the treatment of Diffuse Midline Glioma H3 K27M-Mutant. His top areas of expertise are Diffuse Midline Glioma H3 K27M-Mutant, Brain Stem Cancer, Cerebral Ventricle Cancer, and Glioma.

Advanced in Diffuse Midline Glioma H3 K27M-Mutant
Dr. Alicia C. Lenzen
Pediatric Hematology Oncology
Advanced in Diffuse Midline Glioma H3 K27M-Mutant
Dr. Alicia C. Lenzen
Pediatric Hematology Oncology
225 E Chicago Ave # 30, 
Chicago, IL 
 (0.1 miles away)
312-227-4874
Languages Spoken:
English
See accepted insurances

Alicia Lenzen is a Pediatric Hematologist Oncology provider in Chicago, Illinois. Dr. Lenzen is rated as an Advanced provider by MediFind in the treatment of Diffuse Midline Glioma H3 K27M-Mutant. Her top areas of expertise are Glioma, Medulloblastoma, Diffuse Midline Glioma H3 K27M-Mutant, and Optic Glioma.

Advanced in Diffuse Midline Glioma H3 K27M-Mutant
Dr. Ashley S. Plant
Pediatric Hematology Oncology
Advanced in Diffuse Midline Glioma H3 K27M-Mutant
Dr. Ashley S. Plant
Pediatric Hematology Oncology
225 E Chicago Ave, 
Chicago, IL 
 (0.1 miles away)
800-543-7362
Languages Spoken:
English
See accepted insurances

Ashley Plant is a Pediatric Hematologist Oncology provider in Chicago, Illinois. Dr. Plant is rated as an Advanced provider by MediFind in the treatment of Diffuse Midline Glioma H3 K27M-Mutant. Her top areas of expertise are Diffuse Midline Glioma H3 K27M-Mutant, Medulloblastoma, Optic Glioma, and Glioma.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Morgan's expertise for a condition
ConditionClose
    View All 10 Advanced Conditions
    View All 40 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile